S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

AMLX Amylyx Pharmaceuticals Inc

1.78

-0.11 (-5.82%)

May 10 2024 - Closed

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Amylyx Pharmaceuticals (NASDAQ:AMLX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Amylyx Pharmaceuticals Charts.

Amylyx Pharmaceuticals (NASDAQ:AMLX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Amylyx Pharmaceuticals Charts.

Amylyx Pharmaceuticals Inc News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 9 May 2024 (2 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 9 May 2024 (2 days ago) • Edgar (US Regulatory)

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
Thursday 9 May 2024 (2 days ago) • Business Wire

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
Wednesday 8 May 2024 (3 days ago) • Business Wire

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Thursday 2 May 2024 (1 week ago) • Business Wire

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Wednesday 10 April 2024 (1 month ago) • Business Wire

The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX
Tuesday 9 April 2024 (1 month ago) • PR Newswire (US)

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
Monday 8 April 2024 (1 month ago) • Business Wire

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX
Friday 5 April 2024 (1 month ago) • PR Newswire (US)

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
Thursday 4 April 2024 (1 month ago) • Business Wire

The Gross Law Firm Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX
Tuesday 2 April 2024 (1 month ago) • PR Newswire (US)

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders
Friday 29 March 2024 (1 month ago) • PR Newswire (US)

More Amylyx Pharmaceuticals Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions